Next-Generation GPCR Heteromer Inhibitors for Enhanced Cancer Treatment

A novel approach to GPCR heteromer inhibition, combining CXCR4-HRH1 heteromer inhibitors with chemokine receptor modulators to enhance efficacy and precision in cancer treatment.

The original patent disclosed GPCR heteromer inhibitors for cancer treatment, but its limitations included potential off-target effects and limited understanding of downstream signaling. This new inventive concept addresses these limitations by introducing a synergistic approach, leveraging the interplay between GPCR heteromers and chemokine receptors to create more effective and targeted therapies.

The new inventive concept involves the combination of a GPCR heteromer inhibitor targeting CXCR4-HRH1 heteromers with a chemokine receptor modulator that enhances the efficacy of the inhibitor by altering the chemokine receptor's downstream signaling. This approach enables a more precise and potent inhibition of cancer cell proliferation, while minimizing off-target effects. The system can be administered as a pharmaceutical composition, and the presence of the CXCR4-HRH1 heteromer can be detected using a diagnostic tool.

The new claims introduce a paradigm shift in GPCR heteromer inhibition by incorporating chemokine receptor modulators, which was not anticipated by the original patent. This combination enables a more sophisticated understanding of downstream signaling and allows for more targeted and effective therapies.

Alternative embodiments may include the use of different chemokine receptor modulators, varying the dosage and administration of the pharmaceutical composition, or incorporating additional diagnostic tools to detect other GPCR heteromers. Variations may also include the development of new GPCR heteromer inhibitors targeting different heteromers or the use of CRISPR-Cas9 gene editing to enhance the efficacy of the inhibitors.

The new inventive concept has significant commercial potential in the cancer treatment market, particularly in the development of targeted therapies for specific cancer types. The market for GPCR-targeted therapies is expected to grow significantly in the coming years, and this new approach could capture a substantial share of that market.